A recent study has revealed that an antibody-based blockade might effectively treat cytokine release syndrome (CRS) and alleviate severe cases of COVID-19.
A team of researchers at the Osaka University and Osaka Habikino Medical Center in Japan conducted the recent study. They have now published their findings in the journal Proceedings of the National Academy of Sciences.
The global race to develop a vaccine for SARS-CoV-2 continues. In the meantime, researchers are looking for ways to effectively treat COVID-19, testing both existing drugs and new, experimental therapies.
Because scientists do not fully understand the mechanisms behind severe COVID-19, many doctors are treating it by following the sepsis treatment guidelines.Original Source